Korsana Biosciences (KRSA) has been drawing attention after a sharp year to date share price rise, with the stock closing at $31.20 on 30 September 2026.
The recent pullback, including a 2.5% one day share price decline and a 16.1% drop over the past week, comes after a strong 29.95% 90 day share price return and a very large year to date gain. At the same time, the 1 year total shareholder return of 79.72% contrasts with a weak 5 year total shareholder return that remains deeply negative, suggesting that momentum in Korsana Biosciences is recent and still being tested.
Scan beyond Korsana Biosciences' sharp swing and identify other high-momentum candidates with strong underlying quality using our curated 19 high quality undiscovered gems .
Korsana Biosciences now carries the profile of a high potential biotech, yet that recent surge leaves a different question on the table. Are investors paying a fair price for that story today, or are they already paying up for it?
Preferred multiple of price-to-book: Is it justified?
At $31.20 per share, Korsana Biosciences is not easy to frame using classic valuation shortcuts because it reports no meaningful revenue, a loss of $49.079 million, and carries negative equity. That combination feeds straight into its current Price to Book, which is calculated at a deeply negative level and sits far away from both biotech peers and the broader US market.
The P/B yardstick usually helps investors weigh what they are paying for a company's net assets relative to its market value. For a drug developer like Korsana Biosciences that is still loss making, relies on external funding, and has yet to generate sales, that ratio becomes distorted. A negative equity base means the simple multiple tells you more about past funding structure and accumulated losses than about what the pipeline or THETA platform might be worth.
Instead of leaning on that skewed Price to Book, the more relevant question for a pre revenue biotech is how future cash flows and funding needs could evolve as projects move through the clinic. The SWS DCF model usually tries to answer that by projecting future cash flows and discounting them back to today. In this case, there is insufficient data to run that framework, so the $1.46b market value currently rests on investor expectations around KRSA 028 in Alzheimer's disease and other THETA enabled assets, rather than on an anchored fair value estimate.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Preferred multiple of price-to-book (ABOUT RIGHT)
Still, the entire Korsana Biosciences story leans on unproven KRSA 028 trial outcomes and ongoing access to external funding. Any setback here could rapidly reset sentiment.
Find out about the key risks to this Korsana Biosciences narrative .
Next Steps
Uncertain about whether recent Korsana Biosciences swings leave too much risk on the table or a genuine opportunity in play? Move fast, review the underlying data and filings, and pressure test the concerns that matter most to you with our breakdown of 5 important warning signs .
Looking for more Korsana Biosciences sized opportunities?
If Korsana Biosciences has your attention, do not stop there. Broaden your watchlist with fresh ideas that match your preferred balance of quality, risk, and value.
-
Target potential mispricings by scanning a focused pool of companies screened for quality and value using our 28 high quality undervalued stocks .
-
Build a steadier income stream by reviewing a curated set of higher yielding payers through the 7 dividend fortresses .
-
Sleep easier by concentrating on businesses filtered for stronger financial footing and cleaner balance sheets with the list of solid balance sheet and fundamentals (25 results) .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KRSA .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
